Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sonnet Biotherapeutics Holdings Inc (NQ: SONN )

2.630 -0.140 (-5.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sonnet Biotherapeutics Holdings Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stocks That Hit 52-Week Lows On Thursday
During the morning session on Thursday, 152 stocks hit new 52-week lows. Interesting Points: TotalEnergies (NYSE:TTE) was the biggest company by market cap to set a new 52... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 158 companies reached new 52-week lows. Noteworthy Highlights: The largest company in terms of market cap to set a new 52-week low was Alibaba... 
Via Benzinga
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock moved upwards by 43.27% to $2.45 during Thursday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Tenax Therapeutics (NASDAQ:TENX) ... 
Via Benzinga
Sonnet BioTherapeutics Announces Change in Date of Annual Meeting
- Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ / ACCESSWIRE / June 14, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) Agios Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Aethlon Medical (NASDAQ:AEMD) sto... 
Via Benzinga
Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology
U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
- SON-1010, fully-human IL-12 configured using FHAB platform, advancing towards IND submission - At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE /... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet Bio's Interleukin 12 Candidate For Solid Tumor Shows Encouraging Action Preclinical Studies
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) has a preclinical nonhuman primate GLP repeat-dose study of SON-1010, a proprietary version of Interleukin 12 (IL-12... 
Via Benzinga
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Snowflake (NYSE:SNOW... 
Via Benzinga
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
Stocks That Hit 52-Week Lows On Monday
Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT).... 
Via Benzinga
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
- The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Exposures Product Safety
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
64 Biggest Movers From Yesterday
Gainers Cocrystal Pharma, Inc. (NASDAQ: COCP) shares surged 72.6% to close at $2.14 on Tuesday. Cocrystal Pharma recently announced progress on its COVID-19 antiviral drug... 
Via Benzinga
Exposures COVID-19
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Cocrystal Pharma, Inc. (NASDAQ: COCP) shares jumped 75.4% to $2.1750. Cocrystal Pharma recently announced progress on its COVID-19 antiviral drug candidates that target... 
Via Benzinga
Exposures COVID-19
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
- New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories - Upfront and potential milestone payments totaling up to $21 Million with up to... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
55 Biggest Movers From Friday
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) jumped 45.5% to close at $49.80 on Friday after dropping around 22% on Thursday. Brooklyn ImmunoTherapeutics acquired... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Assertio Holdings (NASDAQ:ASRT) stock increased by 19.41% to $0.62 during Thursday's pre-market session. The company's market cap stands at $107.3 million... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.